Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 10/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 10/20 | 0.52 |
| ▸ | CSF1R | P07333 | 4/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344529 | 0.90 | EHMT2 (0.52) | EHMT2EHMT1SRCSPIN1 | |
| SCHEMBL6336698 | 0.89 | EHMT2 (0.57) | EHMT2EHMT1CSF1RSRCABL1 | |
| SCHEMBL2921747 | 0.84 | DPP4 (0.58) | CSF1RMEN1ALDH1A1KMT2A | |
| SCHEMBL30449564 | 0.84 | DPP4 (0.58) | CSF1RMEN1ALDH1A1KMT2A | |
| SCHEMBL20504510 | 0.83 | EHMT2 (0.52) | EHMT2EHMT1SPIN1 | |
| SCHEMBL6335566 | 0.80 | EGFR (0.60) | EHMT2EHMT1SRCABL1BCR | |
| SCHEMBL6343993 | 0.80 | EHMT2 (0.68) | EHMT2EHMT1SRCABL1BCR | |
| SCHEMBL6343101 | 0.80 | EHMT2 (0.58) | EHMT2EHMT1CSF1RSRCABL1 | |
| SCHEMBL6334819 | 0.79 | SRC (0.53) | EHMT2EHMT1SRCABL1BCR | |
| SCHEMBL30629571 | 0.78 | MAPT (0.62) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1490362-A2 | (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | Millennium Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002072578-A2 | (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | MILLENNIUM PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | WNK2, PDGFA, PDGFRA | EHMT2 4072/4885EHMT1 4143/4885CSF1R 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.